A new targeted therapy might be an option for some patients with high-risk bladder cancers who would rather not have their bladders removed. Joseph Jacob, MD, tells about promising clinical trials of TAR-200 that involve patients from Upstate Medical University. He’s an associate professor of urology at Upstate, specializing in urologic oncology.
“The Informed Patient” is a podcast that covers health, science and medicine, featuring experts from Central New York’s only academic medical center. Upstate Medical University has four colleges (Medicine, Nursing, Health Professions and Graduate Studies); a robust research enterprise; and an extensive clinical health care system that extends way beyond Syracuse.
For more information, please visit: www.upstate.edu/informed/